{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Farrell JJ"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["1485-1493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5119656"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["45(10)"],"pubmed_abstract":["<h4>Objectives</h4>There is a need for validated predictive markers of gemcitabine response to guide precision medicine treatment in pancreatic cancer. We previously validated human equilibrative nucleoside transporter 1 as a predictive marker of gemcitabine treatment response using Radiation Therapy Oncology Group 9704. Controversy exists about the predictive value of gemcitabine metabolism pathway biomarkers: deoxycytidine kinase (DCK), ribonucleotide reductase 1 (RRM1), RRM2, and p53R2.<h4>Methods</h4>Radiation Therapy Oncology Group 9704 prospectively randomized 538 patients after pancreatic resection to receive either 5-fluorouracil or gemcitabine. Tumor DCK, RRM1, RRM2, and p53R protein expressions were analyzed using a tissue microarray and immunohistochemistry and correlated with t"],"journal":["Pancreas"],"pubmed_title":["Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach."],"pmcid":["PMC5119656"],"funding_grant_id":["U24 CA114734","P30 CA060553","U10 CA180868","U10 CA180822","UL1 TR001863"],"pubmed_authors":["Zheng Z","Guha C","Schaefer P","Elsaleh H","Macdonald JS","Regine WF","Benson AB","Yen Y","Moughan J","Liu X","Bepler G","Wong JL","Farrell JJ","Lai R"],"additional_accession":[]},"is_claimable":false,"name":"Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.","description":"<h4>Objectives</h4>There is a need for validated predictive markers of gemcitabine response to guide precision medicine treatment in pancreatic cancer. We previously validated human equilibrative nucleoside transporter 1 as a predictive marker of gemcitabine treatment response using Radiation Therapy Oncology Group 9704. Controversy exists about the predictive value of gemcitabine metabolism pathway biomarkers: deoxycytidine kinase (DCK), ribonucleotide reductase 1 (RRM1), RRM2, and p53R2.<h4>Methods</h4>Radiation Therapy Oncology Group 9704 prospectively randomized 538 patients after pancreatic resection to receive either 5-fluorouracil or gemcitabine. Tumor DCK, RRM1, RRM2, and p53R protein expressions were analyzed using a tissue microarray and immunohistochemistry and correlated with t","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Nov","modification":"2025-04-27T01:21:50.252Z","creation":"2019-03-27T02:29:35Z"},"accession":"S-EPMC5119656","cross_references":{"pubmed":["27748721"],"doi":["10.1097/MPA.0000000000000710","10.1097/mpa.0000000000000710"]}}